$4.13 Billion in Sales Expected for Becton Dickinson and Co (BDX) This Quarter
Brokerages expect that Becton Dickinson and Co (NYSE:BDX) will announce $4.13 billion in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Becton Dickinson and’s earnings. The highest sales estimate is $4.20 billion and the lowest is $4.07 billion. Becton Dickinson and posted sales of $3.08 billion in the same quarter last year, which would indicate a positive year over year growth rate of 34.1%. The firm is scheduled to report its next earnings report on Tuesday, February 5th.
According to Zacks, analysts expect that Becton Dickinson and will report full year sales of $17.45 billion for the current financial year, with estimates ranging from $17.43 billion to $17.50 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $18.44 billion, with estimates ranging from $18.26 billion to $18.73 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Becton Dickinson and.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. The business had revenue of $4.40 billion for the quarter, compared to the consensus estimate of $4.36 billion. During the same period last year, the firm earned $2.40 earnings per share. The company’s quarterly revenue was up 39.0% on a year-over-year basis.
BDX opened at $243.26 on Friday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. Becton Dickinson and has a 1-year low of $209.91 and a 1-year high of $265.87. The company has a market capitalization of $65.41 billion, a price-to-earnings ratio of 22.29, a price-to-earnings-growth ratio of 1.68 and a beta of 1.19.
In other news, EVP James C. Lim sold 5,189 shares of the stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $242.36, for a total value of $1,257,606.04. Following the completion of the sale, the executive vice president now directly owns 13,318 shares of the company’s stock, valued at $3,227,750.48. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Timothy M. Ring sold 42,000 shares of the stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the completion of the sale, the director now directly owns 93,688 shares of the company’s stock, valued at $22,210,614.16. The disclosure for this sale can be found here. Corporate insiders own 1.00% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in BDX. Acropolis Investment Management LLC purchased a new stake in shares of Becton Dickinson and in the third quarter worth $101,000. Almanack Investment Partners LLC. purchased a new position in Becton Dickinson and during the second quarter valued at $105,000. Truvestments Capital LLC purchased a new position in Becton Dickinson and during the third quarter valued at $105,000. Bartlett & Co. LLC grew its stake in Becton Dickinson and by 2,900.0% during the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after acquiring an additional 435 shares in the last quarter. Finally, Bridgeworth LLC purchased a new position in Becton Dickinson and during the second quarter valued at $131,000. 92.60% of the stock is owned by hedge funds and other institutional investors.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Recommended Story: What is a Swap?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.